Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ra Capital Management, Llc Insider Profile
25 Followers
Ra Capital Management, Llc, Former 10% Owner. See FN(1)(6) at Achillion Pharmaceuticals, holds 2.65M shares in Bicara Therapeutics Inc. (Ticker: BCAX), holds 3.11M shares in Fulcrum Therapeutics (Ticker: FULC), holds 18.22M shares in Wave Life Sciences (Ticker: WVE).
Ra Capital Management, Llc Achillion Pharmaceuticals (~ACHN)Former 10% Owner. See FN(1)(6)
Achillion Pharmaceuticals (~ACHN)
Former 10% Owner. See FN(1)(6)
Ranked #60,323 out of 98,834 Corporate Insiders
Profitable Transactions
37 out of 127 Profitable Transactions
Average Return
-1.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Ra Capital Management, Llc's holdings
Insider Roles
Roles that Ra Capital Management, Llc holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ra Capital Management, Llc
Ra Capital Management, Llc's Trading History
Achillion Pharmaceuticals
Jan 20, 2015
―
Informative Buy
7.83M
$32.56M
Aclaris Therapeutics
Sep 19, 2016
Ten Percent Owner
Informative Sell
12.71M
$2.46M
KalVista Pharmaceuticals
Oct 16, 2017
Director
Informative Buy
7.22M
$6.32M
Wave Life Sciences
Aug 14, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$99.65M
Ra Pharmaceuticals
Apr 03, 2020
―
Uninformative Sell
233.20M
$0.00
Eidos Therapeutics
Jun 22, 2018
―
Uninformative Buy
―
$264.30M
Arvinas Holding Company
Oct 03, 2018
Former 10% Owner
Informative Buy
16.00M
$78.37M
Kala Pharmaceuticals
May 26, 2022
Ten Percent Owner
Informative Sell
362.05K
$40.83M
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$617.51M
scPharmaceuticals
Mar 16, 2021
Ten Percent Owner
Informative Sell
1.06M
$14.81M
Satsuma Pharmaceuticals
Jun 12, 2023
―
Uninformative Sell
―
$0.00
89bio
Apr 15, 2024
Director, Ten Percent Owner
Informative Buy
7.49M
$117.80M
Synthorx
Jan 24, 2020
―
Uninformative Sell
661.27M
$0.00
Enliven Therapeutics
Feb 27, 2023
Former 10% owner
Uninformative Buy
―
$46.18M
Phathom Pharmaceuticals
Mar 15, 2021
Ten Percent Owner
Informative Sell
31.06M
$59.90M
Verastem
Jun 29, 2020
Ten Percent Owner
Informative Sell
2.22M
$43.74M
Forma Therapeutics Holdings
Oct 14, 2022
―
Uninformative Sell
―
$0.00
Rhythm Pharmaceuticals
Dec 04, 2020
Former 10% Owner
Informative Sell
7.03M
$233.92M
AKOUOS
Jul 02, 2020
―
Informative Buy
14.03M
$30.32M
Nkarta
Mar 29, 2024
Director, Ten Percent Owner
Informative Buy
30.00M
$56.94M
Pandion Therapeutics
Jul 22, 2020
―
Informative Buy
6.50M
$106.29M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Informative Buy
9.60M
$11.64M
iTeos Therapeutics
May 14, 2024
Former 10% Owner
Uninformative Sell
―
$40.77M
Inhibrx
Aug 24, 2020
―
Uninformative Buy
―
$72.62M
TG Therapeutics
Sep 11, 2020
Ten Percent Owner
Informative Sell
4.09M
$318.90M
Dyne Therapeutics
Sep 23, 2020
Ten Percent Owner
Uninformative Buy
―
$96.33M
PMV Pharmaceuticals
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$2.58M
Vaxcyte
Oct 01, 2020
Ten Percent Owner
Informative Sell
11.24M
$615.78M
Orchard Therapeutics
Nov 06, 2020
―
Informative Buy
3.56M
$165.01M
Iterum Therapeutics
Feb 08, 2021
Ten Percent Owner
Uninformative Buy
―
$12.70M
Vor Biopharma
Dec 09, 2022
Director, Ten Percent Owner
Uninformative Buy
50.00M
$21.25M
Solid Biosciences
Jan 12, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$30.72M
Werewolf Therapeutics
Jan 10, 2023
Director, Ten Percent Owner
Informative Buy
4.10M
$13.64M
Janux Therapeutics Inc
Jun 28, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$443.01M
Aerovate Therapeutics
Jun 20, 2024
Director, Ten Percent Owner
Informative Buy
1.55M
$17.56M
Acumen Pharmaceuticals
Jul 25, 2023
Director, Ten Percent Owner
Informative Buy
40.00M
$36.43M
POINT Biopharma Global
Jun 30, 2021
―
Informative Buy
2.09M
$13.73M
Cytek Biosciences
Mar 16, 2022
Director, Ten Percent Owner
Uninformative Buy
7.19M
$67.71M
Icosavax
Feb 20, 2024
―
Uninformative Sell
―
$0.00
Eliem Therapeutics
Jul 01, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$43.23M
Tyra Bioscience
Feb 08, 2024
Director, Ten Percent Owner
Uninformative Buy
41.37M
$241.67M
Dice Therapeutics
Aug 09, 2023
―
Uninformative Sell
―
$0.00
AN2 Therapeutics, Inc.
Aug 13, 2024
Ten Percent Owner
Informative Sell
3.81M
$318.90K
PepGen Inc.
Feb 13, 2024
Director, Ten Percent Owner
Informative Buy
27.21M
$98.99M
ARS Pharmaceuticals
Mar 27, 2024
Director, Ten Percent Owner
Informative Buy
13.29M
$152.60M
Fulcrum Therapeutics
Aug 23, 2024
Ten Percent Owner
Uninformative Sell
―
$10.70M
Mineralys Therapeutics, Inc.
Feb 14, 2024
Director
Uninformative Buy
22.58M
$56.71M
Black Diamond Therapeutics
Jul 07, 2023
Director
Informative Buy
4.68M
$16.68M
LENZ Therapeutics
Mar 25, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$29.87M
Boundless Bio Inc.
Apr 04, 2024
Ten Percent Owner
Uninformative Buy
―
$1.03M
Acrivon Therapeutics, Inc.
Apr 15, 2024
Director, Ten Percent Owner
Uninformative Buy
30.00M
$63.05M
Cidara Therapeutics
Jul 22, 2024
Director
Uninformative Buy
―
$8.17M
Artiva Biotherapeutics, Inc.
Jul 24, 2024
Director, Ten Percent Owner
Uninformative Buy
4.71M
$9.84M
Bicara Therapeutics Inc.
Sep 18, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$68.25M
Sangamo Biosciences
Feb 18, 2015
Former 10% Owner
Informative Buy
176.95K
$4.61M
Biospecifics Technologies
Feb 26, 2010
―
Informative Sell
288.30K
$55.46M
Dicerna Pharma
Feb 05, 2014
―
Informative Buy
15.00M
$193.93M
Sequenom
―
―
―
$27.21M
Curis
―
Ten Percent Owner
―
$36.63M
Derma Sciences
Jan 13, 2014
―
Informative Sell
3.55M
$11.86M
Aradigm
―
―
―
$49.74K
List of latest transactions for each holding click on a transaction to see Ra Capital Management, Llc's performance on stock
You May Also Like
Ra Capital Management, Llc insider profile FAQ
What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 29%.
What is the average return per transaction made by Ra Capital Management, Llc?
The average return per transaction made by Ra Capital Management, Llc is -1.00%.
What stocks does Ra Capital Management, Llc hold?
Ra Capital Management, Llc holds: ~ACHN, ACRS, KALV, WVE, RARX, EIDX, ARVN, KALA, ~THOR, SCPH, STSA, ETNB, THOR, ELVN, PHAT, VSTM, FMTX, RYTM, AKUS, NKTX, PAND, INZY, ITOS, ~INBX, TGTX, DYN, PMVP, PCVX, ORTX, ITRM, VOR, SLDB, HOWL, JANX, AVTE, ABOS, PNT, CTKB, ICVX, ELYM, TYRA, DICE, ANTX, PEPG, SPRY, FULC, MLYS, BDTX, LENZ, BOLD, ACRV, CDTX, ARTV, BCAX, SGMO, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
What was Ra Capital Management, Llc’s latest transaction?
Ra Capital Management, Llc latest transaction was an Uninformative Buy of ―.
What was Ra Capital Management, Llc's most profitable transaction?
Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
What is Ra Capital Management, Llc's role in Achillion Pharmaceuticals?
Ra Capital Management, Llc's role in Achillion Pharmaceuticals is Former 10% Owner. See FN(1)(6).
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.